Welcome to the Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC)
If you have been diagnosed with Waldenstrom’s Macroglobulinemia (WM) or care for someone who has, welcome to the WMFC family of WM patients, caregivers, friends and relatives. We are a community providing support, research and information on WM.
Sign up for our newsletter below to receive updated information.
**Ensure you receive all the latest news on research, events, the Torch and support by keeping your email up to date and including WMFC and IWMF as trusted senders as well as keeping your mailing address up to date.
OCT 27th 2018
Watch for our fall WM Newsletter
Article: Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients with Waldenstrom MacroglobulinemiaAbstract: Purpose Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations (MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective study of ibrutinib monotherapy Read More